参考文献/References:
[1] 侯飞,车宏伟,张宇佳,等.阿司匹林临床应用研究进展[J].中国药物评价,2018,35(05):349-352.
[2] 佟玉.低剂量阿司匹林在辅助生殖技术中不同时期的应用研究[D].大连:大连医科大学,2011.
[3] 张文琼,刘东亮,胡新荣,等.ACS抗血小板治疗进展[J].空军医学杂志,2018,34(05):351-354.
[4] Algutkar AS,Crews BC,Rowlinson SW,et al.Biochemically based design of cyclooxygenase-2(COX-2)inhibitors:facile conversion of nonsteroidal anti-inflammatory drugs to potent and high-ly selective COX-2 inhibitors[J].Proc Nati Acad Sci,2000,97(2):925-930.
[5] Kang X,Chen G,Cao WJ,et al.Cyclooxygenase-1 and its selective inhibitors:Research progress and perspectives[J].Chin J Antibio,2016,10(41):727-734.
[6] Radi ZA,Khan NK.Effects of cyclooxygenase inhibition on the gastrointestinal tract[J].Exp Toxicol Pathol,2006,58(2/3):163-173.
[7] Yang Y,Sun R,Cao YH.Research progress on the effect of selective COC-2 inhibitors on cardiovascular diseases[J].J Pharm Res,2016,35(01):41-45.
[8] Kang YJ,Mbonye UR,Delong CJ,et al.Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation[J].Prog Lipid Res,2007,46(2):108-125.
[9] 史小四,郭喆,叶林,等.环氧化酶抑制药的临床应用进展[J].医药导报,2008,12(27):1491-1493.
[10] Fuster V,Sweeny JM.Aspirin a historical and contemporary therapeutic overview[J].Circulation,2011,123(7):768-778.
[11] Sneader W.The discovery of aspirin: a reappraisal[J].Br Med J,2000,321(7276):1591-1594.
[12] Simmons DL,Botting RM,Hla T.Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition[J].Pharmacol Rev,2004,56(3):387-437.
[13] Chang CC,Chuang CL,Lee WS,et al.Selective cyclooxygenase-1 inhibition improves collateral vascular reactivity in biliary cirrhotic rats[J].Journal of the Chinese Medical Association,2013,76(10):557-563.
[14] Li S,Liu B,Luo W,et al.Role of cyclooxygenase-1 and-2 in endothelium-dependent contracti-on of atherosclerotic mouse abdominal aortas[J].Clin Exper Pharm Physiol,2016,43(1):67-74.
[15] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.抗血小板治疗中国专家共识[J].中华心血管病杂志,2013,41(3):183-194.
[16] Lordkipanidze M,Pharand C,Schampaert EA,et al.A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease[J].Eur Heart J,2007,28(14):1702-1708.
[17] Roger VL,Go AS,Lloyd-Jones DM,et al.Heart disease and stroke statistics--2011 update: a report from the American Heart Association[J].Circulation,2011,123(4):e18-e209.
[18] Kuliczkowski W,Witkowski A,Polonski L,et al.Interindividual variability in the response to oral antiplatelet drugs:a position paper of the working group on antiplatelet drugs resistance appointed bythe Section of Cardiovascular Interventions of the Polish Cardiac Society,endorsed by the working group on Thrombosis of the EuropeanSociety of Cardiology[J].Eur Heart,2009,30(4):426-435.
[19] Awa K,Satoh H,Hori S,et al.Prediction of time-dependent interaction of aspirin with ibuprofen using a pharma-cokinetic/pharmacodynamic model[J].J Clin Pharm Ther,2012,37(4):469-474.
[20] Loscalzo J.Nitric oxide insufficiency,platelet activation,and arterial thrombosis[J].Circ Res,2001,88(8):756-762.
[21] Santilli F,Vazzana N,Liani R,et al.Platelet activation in obesity and metabolic syndrome[J].Obes Rev,2012,13(1):27-42.
[22] Parodi G,Marcucci R,Valenti R,et al.High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI[J].JAMA,2011,306(11):1215-1223.
[23] Kosaka T,Miyata A,Ihara H,et al.Characterization of the humangene(PTGS2)encoding prostag-landin-endoperoxide synthase 2[J].Eur J Biochem,1994,221(3):889-897.
[24] Lepäntalo A,Mikkelsson J,Reséndiz JC,et al.Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients[J].Thromb Haemost,2006,95(2):253-259.
[25] Maree AO,Curtin RJ,Chubb A,et al.Cyclooxygenase-1 haplotype modulates platelet response to aspirin[J].J Thromb Haemost,2005,3(10):2340-2345.
[26] Fan L,Cao J,Liu L,et al.Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease[J].Gerontology,2013,59(2):122-131.
[27] Halushka MK,Walker LP,Halushka PV.Genetic variation in cyclooxygenase 1: Effects on response to aspirin[J].Clinical Pharmacology & Therapeutics,2003,73(1):122-130.
[28] Ulrich CM,Bigler J,Sparks R,et al.Polymorphisms in PTGS1(=COX-1)and risk of colorecta-l polyps[J].Cancer Epidemiol Biomarkers Prev,2004,13(5):889-893.
[29] Kosaka T,Miyata A,Ihara H,et al.Characterization of the human gene(PTGS2)encoding prostaglandin-endoperoxide synthase 2[J].Eur J Biochem,1994,221(3):889-897.
[30] Cambria-Kiely JA,Gandhi PJ.Aspirin resistance and genetic polymorphisms[J].J Thromb Thrombolysis,2002,14(1):51-58.
[31] 杨蓉,焦洁茹,蔡伟,等.阿司匹林抵抗与基因多态性的相关性研究[J].诊断学理论与实践,2009,8(6):623-626.
[32] Kunicki TJ,Kritzik M,Annis DS,et al.Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence[J].Blood,1997,89(6):1939-1943.
[33] Homoncik M,Jilma B,Hergovich N,et al.Monitoring of aspirin(ASA)pharmacodynamics with the platelet function analyzer PFA-100[J].Thromb Haemost,2000,83(2):316-321.
[34] Moshfegh K,Wuillemin WA,RedondoM,et al.Association of two silent po lymorphisms of plate-let g lycoprotein Ⅰa/Ⅱa receptor with risk of myocardial infarction:a case-control study[J].Lancet,1999,353(9150):351-354.
[35] Verschuren JJ,Trompet S,Wessels JA,et al.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?[J].Eur Heart J,2012,33(2):165-U148.
[36] Goodman T,Ferro A,Sharma P.Pharmacogenetics of aspirin resistance: a comprehensive systematic review[J].Br J Clin Pharmacol,2008,66(2):222-232.
[37] Wurtz M,Nissen PH,Grove EL,et al.Genetic determinants of on-aspirin platelet reactivity:focus on the influence of PEAR1[J].PLoS One,2014,9(10):e111816.
[38] 卜庆乐.PEAR1基因多态性增加中国汉族人群缺血性脑卒中患者阿司匹林抵抗易感性[D].青岛:青岛大学,2017.
[39] 王向杰,许青宗,宋金玲,等.PEAR1基因多态性与冠心病PCI术后阿司匹林抵抗及预后的关系[J].中国临床研究,2018,31(3):308-312.
[40] Peng LL,Zhao YQ,Zhou ZY,et al.Associations of MDR1,TBXA2R,PLA2G7,and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy[J].Acta Pharmacol Sin,2016,37(11):1442-1448.
[41] Jalil NJ,Bannur Z,Derahman A,et al.The implication of the polymorphisms of COX-1, UGT1A6, and CYP2C9 among cardiovascular disease patients treated with aspirin[J].Journal of Pharmacy and Pharmaceutical Sciences,2015,18(3):474-483.
[42] Sanak M,Simon HU,Szczeklik AC.4(sup)synthase promoter polymorphism and risk of aspirin-induced asthma[J].Lancet,350(9091):1599-1600.